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I) Introduction 
1. Central nervous system diseases and glia 
Central nervous system (CNS) diseases are neurological disorders affecting the function or the 
structure of the brain and the spinal cord. There is a great number of different types of CNS 
diseases, spanning from addiction to neurodegenerative disorders. The treatments for those 
diseases often consist in medication. However, drugs affecting the brain usually come with 
important and frequent adverse effects or lack of response, varying between individuals [12].  
A combination of a psychotropic and a secondary drug meant to either remove the adverse 
effects or enhance the psychotropics’ efficacy can be considered as a potential solution for 
this problem. The choice of the secondary drug requires to find the target that is responsible 
for the psychotropic’s limitations. Over recent years, some psychotropic have been 
determined to have secondary effects on the glia [13], potentially outlining a new type of 










Figure 2. Glial cells – neurons interactions. [14] 
Glial cells are the neuron’s environmental cells. They constitute around 50% of the brain 
volume. They are mainly divided in 3 different types: microglia, astrocytes and 




the recent decades have proven that assumption to be false. The glial cells have been found 
to control multiple aspects of the development and wiring of the brain, as well as providing 
the metabolic support to neurons and regulating cell-cell interactions [16]. Despite these 
many discoveries, many of the mechanisms behind their function have yet to be discovered. 
 
2. Drug Repurposing/Repositioning 
The development of a new drug is an expensive, complex and lengthy process costing up to 
billions of dollars and taking up to decades for a single drug [1]. Furthermore, developing a 
drug is always a risky venture as the success rate for the FDA (USA) evaluations is only around 
10% [2] and once the drug is fully developed and marketable, there is still a risk of commercial 
failure.  
Drug development, while it has the potential to be highly profitable, can fail on many steps of 









Figure 1. Comparison of Drug Development Costs with Revenue Earned After Approval. [4] 
In an effort to reduce the risks and the costs, drug repurposing (also called drug re-tasking, 
drug repositioning or drug reprofiling) offers an alternative to the classic approach of drug 
development [5]. Drug repurposing is the process in which already registered and studied 




most of development costs as well as having more confidence for safety studies as those have 
already been conducted for the first commercialization of the compound [1]. 
This process started by empirical discoveries of drugs effects on pathologies they were not 
supposed to affect. It has now evolved into the use of bioinformatics tools to determine new 
potential substances usages [6].  
Those bioinformatics tools use computational approaches to predict novel uses by exploiting 
various data such as gene expression profiles, protein targets, pharmaceutical mechanisms, 
etc [7] [8].  The information is exploited by creating networks of similarities between drugs 
thus determining which drugs could potentially find new uses [9]. However, those tools are 
not foolproof. Most of the data generated will be predicted but not proven, therefore the 
results always have to be considered with caution and be considered only as potential ways 
to explore via future experiments. 
 
3. Drugs combination 
The combination of multiple drugs is an old practice that can be traced back to millennia ago. 
Those drugs were developed to target a single disease at first but it has recently begun to be 
used to treat multiple diseases at once [10]. 
The many discoveries in biology these past decades allow for a better understanding of 
diseases and of the drug used as treatment, allowing science to progress from empiric 
discoveries to theoretical possibilities. It is now possible to determine if a disease can be better 
treated by targeting one or multiple targets and the drugs secondary effects can be modulated 
as well [11].  This opens the opportunity for drugs combination which offers multiple benefits 
compared to simple drugs such as:  
- Increased efficacy: one drug enhancing another one by blocking the elimination process.  
- Increased efficacy: one drug enhancing the properties of the other without modulating its 
PK parameters. The only interaction would be pharmaco-dynamic (additional effect). 





4. Rationale and Objective 
The aim of this internship is to develop a tool to predict potential drug combinations for brain 
pathologies. 
An important proportion of the drugs used to treat central nervous system diseases target 
neurotransmission while also impacting the glia. We make the hypothesis that this secondary 
effect is be detrimental but can be modulated by a secondary drug that could be combined 
with the psychotropic. 
This tool would look for a selected neuronal drug’s secondary effects on the glia by exploring 
the multiple databases available online and extracting the recorded drug interactions. From 
those interactions their pathways’ contents are selected and filtered to obtain as output the 
name of the potential glial targets that could be modulated through a second drug.  
The first part of the internship consisted in finding databases containing potentially relevant 
data to our objective to then gather data from the different sources chosen in RDF format. For 
some of those databases, the data are freely accessible online and need no further work but 
other databases require to download their data and re-create the database locally, sometimes 
needing to be converted to the appropriate RDF format as well. The second part consisted in 
exploring the gathered databases with SPARQL queries and creating an outline of all the 
information that needs to be extracted to make an appropriate selection. This selection will 
then remove irrelevant data to our study to retain only glia results. 
We focused on Modafinil, a drug used to treat excessive daytime sleepiness in narcoleptic 
patients, as a proof of concept. An interaction between Modafinil and two glial targets, the 
connexins 30 and 43, has been discovered in the past years [17] but is not indicated in drugs 
or targets databases. As such, finding the connexin in the results, while not a foolproof 







II) Materials and methods 
1. RDF/SPARQL 
Resource Description Framework (RDF) is a model of graph designed to store data and 
metadata. It was developed by the World Wide Web Consortium (W3C) and is the Semantic 
Web’s main language. It is not formally considered a format but a data model. There are 
multiple RDF formats such as RDF/XML, Turtle, JSON-LD, OWL, etc. 
RDF is based on the concept of a triple: subject, predicate and object. The predicate declares 
a relationship between the subject and the object thus creating a statement.  A collection of 
these statements represents a directed multi-graph. The data stored under the RDF model 
can be accessed in two ways: locally or remotely. The remote access is done through 
endpoints, these endpoints are links to access the data stored within.  
 
SPARQL is a query language used to retrieve and manipulate data stored in an RDF format. 
The name is a recursive acronym: SPARQL Protocol And RDF Query Language. It is one of the 
major technologies of the Semantic Web which is constituted of hundreds of SPARQL services 
offering access to huge amounts of data, growing continuously [18]. 
 
Virtuoso is a query service allowing for SPARQL queries on multiple remote data endpoints at 
once. This type of query going through multiple databases is called a federated query. 
However, for those federated queries to work, it is necessary for the multiple endpoints used 
to possess common identifiers for compounds as to be able to connect them.  
Unfortunately, this is not the case for all the databases that were used for this internship. The 
solution consisted in using Python to convert queries’ results to make them useable by other 







Two Python packages were used to execute the SPARQL queries: 
- RDFLib [19] is a library containing an RDF/XML parser and is used on local RDF files that 
could not be stored in endpoints. 
- SPARQLWrapper is a wrapper around a SPARQL service. It is used to send queries on 
endpoints directly from Python and return the results in a easily useable format.  
 
AskOmics [20] is a visual SPARQL query interface supporting both intuitive data integration 
and querying while shielding the user from most of the technical difficulties underlying RDF 
and SPARQL. In this project, it has been be used to convert databases that are not available in 
RDF but that are available in tsv/csv format. This software will convert files in such format into 
a RDF format.  
AskOmics also offer the possibility to load RDF data into a local private endpoint. 
 
 
2. Data used 
We looked mainly for two types of databases: 
- Drug databases from which we could extract the drugs recorded interactions as well as the 
sources documenting them. 
- Target databases containing proteins, genes and pathways as to link the drugs’ databases 




















Figure 3. Structure of the Uniprot SPARQL endpoint. [21] 
On this figure is the example of a classic RDF structure, in this case the Uniprot endpoint. From 
the Uniprot accession number, the entire data associated is accessible through the 
corresponding relations. If the accession number is not known, it is possible to obtain it if 
enough of the associated data is known as the triples in the RDF model work both ways.  
For example, the entry P17302 is the entry for the connexin 43. You can obtain the mnemonic 
name with the following relation: 
                                            VALUES (?entry){up_core:P17302} 
?entry      up_core:mnemonic      ?mnemonic  
                                          Subject        Predicate            Object   
 
If the mnemonic name is known but no the entry, this relation can be used as well. 
VALUES (?mnemonic){up_core:CXA1_HUMAN} 




This is however one of the simpler structures as, like biopax3 which is used by the Ensembl 
endpoint. some can prove more complicated  
 














a. Drug databases 
The input of the pipeline being a drug, the first step is to find drug databases. The IDs from 
other databases as well as the known interactions (and their sources) will be extracted from 




8 databases were considered: 
Database Description Data of interest 
DrugBank [23] Freely accessible database, it contains 
information on drugs and drugs targets. 
There are 13 338 drug entries as of April 
2019. It is one of the most widely used drug 
databases and naturally came up when we 
began searching. 
Proteins interactions 
PubChem [24] Database of chemical molecules and their 
activities against biological assays. There are 
97 million compounds entries. 




Collection of information about genes and 
proteins from 114 datasets provided by 66 
online resources. 
Proteins and genes 
interactions 
PharmGKB [26] Pharmacogenics knowledge resource that 
encompasses clinical information including 
clinical guidelines and drug labels, 
potentially clinically actionable gene-drugs 
associations and genotype-phenotype 
relationships. 
Proteins and genes 
interactions 
KEGG [27] Database resource for understanding high-
level functions and utilities of the biological 
systems. 
Proteins and genes 
interactions 
ChEMBL [28] Manually curated database of bioactive 
molecules with drug-like properties. It brings 
together chemical, bioactivity and genomic 
data to aid the translation of genomic 
information into effective new drugs. 





Wikidata Free and open knowledge base that can be 
read and edited by both humans and 
machines. Wikidata acts as central storage 
for the structured data of its Wikimedia 
sister projects including Wikipedia, 
Wikivoyage, Wiktionary, Wikisource, and 
others. 
IDs for drugs and 
interactions 
DGIdb [29] Drug-gene interaction database. Genes interactions 
 
Out of those 8 databases, 2 were not used:  
KEGG is one of the most complete databases available online and could have brought plenty 
of data on both drugs and targets. Unfortunately, it does not offer programmatic access and 
is not available to download for free. Therefore, it was taken out of the list of drugs databases. 
PubChem gathers an important part of all other drugs databases as well as providing bioassays 
which could have brought new possibilities for target identification. However, the API offers 
only partial access to the database. It is available for download in RDF, and it is possible to re-
create the database locally but it required a 500 Go SSD with 64 Gb of memory. The possibility 
of using the GenOuest platform to upload the database in the cloud was considered, however 
due to the short duration of the internship, this would have been a complicated and time-
consuming process for only a few weeks of use. 
 
It should be noted that this choice of database is not exhaustive, the main point of focus for 
this selection, after their availability, are the drug’s interactions. The objective in gathering 
the maximum of databases is to have a maximum of known interactions, as those differ from 
database to database.  Since there is no centralized database that gathers all the information 
from all the available sources, we are left with the only option of exploring as many databases 





b. Target databases 
Next are the target databases, the objective there is to gather enough data on the most 
commons targets, being genes and proteins.  
Three databases were selected: 
Database Description Data of interest 
Uniprot [21] Freely accessible database of 
protein sequences and 
functional information 
Proteins 
Ensembl endpoint [30] Genome browser for 
vertebrate genomes 
Proteins/Genes 




c. Database Availability 
Database Status 
DrugBank Downloadable in XML 
PharmGKB Downloadable in TSV 
DGIdb Downloadable in TSV 
Wikidata Endpoint freely accessible 
Harmonizome Outdated API 
Uniprot Endpoint freely accessible 
Ensembl/ChEMBL Endpoint freely accessible 





PharmGKB and DGIdb were available to download freely, not in RDF but instead in TSV. Some 
small modifications were necessary, mostly in the columns’ names but also in some of the 
data which contained unreadable symbols, to make the files readable by AskOmics. The 
software then converted the two databases in RDF. These were then accessible through the 
local endpoint created by the software. 
DrugBank was downloadable in one XML file of 1.7 Gb. I developed a Python script using the 
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The parser will scan the entire file and extract a DOM tree on which it will be possible to select 
elements by name. The major inconvenient with this parsing method is that the file is being 
loaded up entirely and re-created in DOM format. While this is not a problem with small files, 
the DrugBank database weights 1.7 Gb which can be a problem depending on the computer’s 
power.                                                                                      
                                                                                                                   
From there, data of interest can be extracted with the function getElementsByTagName(). 
However, this function is recursive, meaning it will search for the given tag name in every 
subsection of the tree. The parser cannot make the difference between a drug tag referencing 
a Drug entity and a Drug-Drug interaction. The workaround here is to use the attributes 
provided in the tags. For example, a Drug entity tag will add information such as: 
<drug type=”biotech” created=”01/01/2000”>  
 
Not all of the data provided was kept for the conversion as some of it was not necessary and 
would have slowed the conversion and led to heavier files which would have slowed the 
SPARQL queries  
The following data was kept:  
Identification: Name / DrugBank ID / CAS ID / ATC ID / External IDs 
Interactions: Targets / Drug-Drugs interactions / Drugs-Proteins interactions / GO terms / 
PubMed References 
The database was converted in two ways: one file for the entire database and one file per drug 
(15 000 files in total). The objective was to find which solution was optimal. The conversion 















Figure 6. The two ways considered to convert DrugBank from XML to Turtle. 
Converting into one file amounted to a smaller size since the prefixes at the beginning of each 
turtle file was only necessary once but the difference was only of 6 Mb (around 3%).  
As for queries, they are much slower when looking for data on a single drug on the whole 
database rather than on one drug file (around 10 minutes against 6 seconds).  This means the 
multiple files method is much more practical and was thus selected. However, the drawback 
is that since drugs are within separate files, it is not possible to execute a query on multiple 
drugs at once, instead requiring multiple queries whereas only one would have been 
necessary with the whole database in one file. 
 
Harmonizome has an API that is programmable through Python, but the documentation is 
outdated making the API unusable. However, on each of the database’s entity webpage, it is 
possible to retrieve the full page’s data in JSON format. This was used by creating a Python 
script with the urllib package to query the URI leading to this JSON formatted data which could 
then be extracted. 
At this point, all databases are accessible and connected. The SPARQL queries are carried out 
through the Python package SPARQLWrapper (with the exception of DrugBank for which the 
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Figure 7. How the data was extracted 
Python is used here for multiple reasons: 
-It allows to execute multiple SPARQL queries at once  
-Connecting some of the databases can prove tedious due to differences in the way data is 
stored. Python allows us to convert results from a query to make them readable to another 
database. The vast amount of packages also ensures that there is a way to use the data in 
whatever format it is. 
-The access to Harmonizome was done through the designed Python API at first and some 
elements of this API have been recycled to be used with the URL parser. 
Throughout the internship, there was no noticeable difference between the query time of 










2. Connections between Databases 
 
 
Figure 8. Connections between our list of databases. 
A connection in the graph, means that it is possible to obtain from DatabaseA a matching ID 
for an element in DatabaseB. Technically, it is possible to go from almost any database to 
another simply with the element name but what is shown in the figure are the direct links 
between them. 
Here we can observe that our set of databases is well connected, with the exception of the 








3. Pipeline with Modafinil 
Figure 9.  Pipeline’s path through selected databases when extracting the potential proteins 
interactions of Modafinil 
The pipeline input is the name of the drug, in this case the Modafinil. With this, a query is 
made on Wikidata to extract the DrugBank ID. This query is necessary as the DrugBank 
database is the only one of those selected from which data cannot be extracted merely with 




Queries are then sent to the drugs databases, the Drugs-Target interactions and the sources 
documenting those are extracted. Three kind of interactions are obtained: proteins, genes and 
genes variants, this last category is not used for the rest of the pipeline as there is no gene 
variants database in our list. 
WikiPathway is then used to extract all the pathways which contain the genes and proteins 
interacting with the drug.  The content of those pathways is then stored. 
However, all the results returned by WikiPathways are not relevant since we are looking for 
glial results. In an effort to make the results more relevant and to reduce their number, some 
selections will be made: 
- The pathways that do not take place in the brain are removed. A threshold is set where a 
given percentage of the pathway’s proteins have to be present in the brain. This percentage 
is not 100% because the databases are not exhaustive and the ontology for some of the 
proteins might not be complete leading to some pathways being relevant but removed 
because of a few elements. 
- The pathways are given a score. This score is computed on the size of the pathway and the 
amount of recorded interactions occurring in this pathway. 
- The proteins are given a score. This score is computed on the amount of times the protein 
appears in the results and on the score given to the pathway from where it’s coming from. 
 




Out of all the drugs databases, a total of 30 interactions have been extracted. They are 
constituted of 16 genes, 11 proteins and 3 variants. As it has been said before, there is no 
variant database in our list at the moment so those interactions are not used. 
After searching in the pathways containing the interactions, we extracted a total of 9358 




brain. This filtration is not made on the glia yet because Uniprot does not have that level of 
precision, the purpose is to reduce the amount of results and gin time for the next step. This 
selection is not done with one of the databases from our list but with a list of glial genes 
coming from an external source. After this selection, we are left with 1016 results. In these 




There is plenty of information available on the many online databases publicly available. 
However, this information is dispersed. The recorded drug interactions for example, differ 
greatly from one database to the other even if some elements are constant.  
Few of those many databases were directly available through RDF, whether it is because they 
are not stored this way or because they chose not to give full access to their data. Some of the 
most important databases (Uniprot and Ensembl for example) provide a freely accessible RDF 
endpoint via Virtuoso which make them very easy to access and eventually connect to other 
databases. It should be noted that those two endpoints are already linked, with the 
documentation in both of those indicating how to do so. Unfortunately, there are no major 
drugs databases offering that same service at the exception of ChEMBL which is included in 
Ensembl.  In spite of this, we have established that it is possible to integrate them in a RDF 
network of databases but it is a precarious answer. Since the data is downloaded, it is not kept 
to date with the live database and gets no update, potentially meaning that an error in the 
data could stay until the next download. It also means it is necessary to re-download each 
time a database is updated, which is a doable but inconvenient process. 
Furthermore, the files available for download sometimes present errors or discrepancies such 
as names miswritten or written differently (chemical name instead of usual name). In TSV files, 
some of the information is sometimes placed in the wrong column. 
What is surprising about this state of things is that plenty of databases either used to be 




project to gather them inside a global endpoint. Those endpoints are not activated anymore 
but can still be found on Bio2RDF, a biological database designed to gather RDF databases. 
 
The availability of the database is not the only blocking step to establish a network of 
connections. One important issue is the structure of the information. In our case, there is no 
problem with DGIdb, DrugBank or PharmGKB because there is a direct access to the files and 
we can control how to set up the data inside the local AskOmics endpoint or in the Turtle files. 
Because of this, we have full knowledge on the way the data is contained and can easily create 
SPARQL queries. However, this is not the case for the public endpoints of Uniprot and 
Ensembl. Those are both huge databases containing many different types of information 
which need to be stored and linked together. This results in a complex data network which 
design’ is either specific to the database or following a set of rules. In our case, Uniprot has 
it’s own specific structure while Ensembl is constructed under the biopax3 model. In both 
cases, the understanding of the structure can be tedious especially when the documentation 
provided is incomplete, erroneous or imprecise which can be the case for both those 
databases. For example, some of the prefixes and relationships between entities indicated in 
the Uniprot documentation either do not exist or are wrongly flagged. As for Ensembl, the 
documentation for the biopax3 model is very basic, despite it being deep and complex, which 
means it is necessary to search for a more thorough documentation elsewhere. Fortunately, 
example queries are provided for the two endpoints which helps as a good introduction for 
both simple and more complex queries but there is few of them and they do not reflect the 
vast amount of information available. 
2. Results relevance 
There are several factors that need to be taken in account in order to consider our results. 
Firstly, every result obtained is entirely dependent of the databases’ validity. Because we are 
gathering data from multiple sources to gather as much information as possible instead of 
cross-examining it, any erroneous result from the database could not be filtered. If an error in 
a drug data happened to slip by in a drug database, there would be very little way for us to 
detect it. The solution here lies solely on the choice of the databases and the careful 




positive results but not false negative ones since they would be automatically removed from 
our results before we could manually detect the error.  
Secondly, the design of the pipeline is debatable as well, exploring the pathways is but one of 
the many possibilities for exploring the available databases. Multiple options were considered 
and this one was selected because it was considered pertinent and practical. An interaction 
between a drug and a gene or a protein could logically impact the levels of a molecule from 
that pathway, but not necessarily. The results obtained are solely predictions and not 
confirmed interactions, as those could only be obtained via experiments. 
 
3. Results 
We have a total of 1016 proteins as results. This is a number too big to draw conclusions on 
the relevance of this method, however the two targets that were supposed to be found 
(connexins 30 and 43) do come up in our list which is an encouraging sign. The pathway 
filtration has yet to be implemented and may be the decisive step to determine if those results 
came up by chance or not. If the proteins are ranked by score, the important amount of 
proteins is not going to be a problem since we will be able to know which ones are truly 
relevant and which are not.  
 
4. Generalization 
Aside from the functions currently being implemented (pathway and proteins statistical 
selection as well as glial filtration), there is a lot of room for improvement of the pipeline. For 
starters, more databases could be used to potentially gather interactions that were not 
recorded within our own set of databases. A variant database would also be necessary to 
utilize the variants interactions. 
But overall, there is an almost endless amount of possibilities when accessing such large 
databases. The list of databases chosen, now that they’re gathered and linked together, can 
be used as basis for an entirely different focus just as it could be used to complement the 




of time, possess Bioassays which could be used to compute similarities between multiple 
drugs. This way, we could potentially predict common genes and proteins interactions 
between drugs. Overall, each database added to the list from this point could bring a new 
potential type of analysis. 
 
IV) Conclusion 
There is a huge amount of publicly available information online, whether it is under a RDF 
format or not. With the exception of a few databases making the deliberate choice of not 
providing their data, this information is easily accessible, mostly through downloadable files 
and some databases even provide a free direct programmatic access.  
As for the objective of this internship, we obtained a total of 1016 proteins which is too much 
to consider it achieved at this point. However, the proteins used as validation are present in 
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